Anti-cancer Activities of Ginseng Extract Fermented with Phellinus linteus

In the present study, the anti-cancer effects of ginseng fermented with Phellinus linteus (GFPL) extract were examined through in vitro and in vivo assays. GFPL was produced by co-cultivating ginseng and Phellinus linteus together. Ginsenoside Rg3, Rh1 and Rh2 are important mediators of anti-angioge...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mycobiology 2009, 37(1), , pp.21-27
Hauptverfasser: Lee, J.J., Whanin Pharm. Co., Ltd., Suwon, Republic of Korea, Kwon, H.K., Whanin Pharm. Co., Ltd., Suwon, Republic of Korea, Jung, I.H., Whanin Pharm. Co., Ltd., Suwon, Republic of Korea, Cho, Y.B., Whanin Pharm. Co., Ltd., Suwon, Republic of Korea, Kim, K.J., Kangnung National University, Kangnung, Republic of Korea, Kim, J.L., Whanin Pharm. Co., Ltd., Suwon, Republic of Korea
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In the present study, the anti-cancer effects of ginseng fermented with Phellinus linteus (GFPL) extract were examined through in vitro and in vivo assays. GFPL was produced by co-cultivating ginseng and Phellinus linteus together. Ginsenoside Rg3, Rh1 and Rh2 are important mediators of anti-angiogenesis and their levels in GFPL were enriched 24, 19 and 16 times, respectively, more than that of ginseng itself through the fermentation. GFPL exhibited distinct anti-cancer effects, including growth inhibition of the human lung carcinoma cell line A549, and promotion of immune activation by stimulating nitric oxide (NO) production in Raw 264.7 cells. Further evidence supporting anti-cancer effects of GFPL was its significant prolongment of the survival of B16F10 cancer cell-implanted mice. These results suggest that the GFPL may be a candidate for cancer prevention and treatment through immune activation and anti-angiogenic effects by enriching Rg3, Rh1 and Rh2.
ISSN:1229-8093
2092-9323
DOI:10.4489/MYCO.2009.37.1.021